AUTHORS
Stephanie Wu, MD, Daniel Ng, MD2, Xinyi Du3, Mareen Kassabian, BS4, Alysia Bosworth, BA5, Lanie Lindenfeld6, Andrew Artz, MD,MS7, Monzr M. M Al Malki, MD8, Ryotaro Nakamura, MD9, Guido Marcucci, MD10, F. Lennie Wong, PhD11, Faizi Jamal, MD12, Saro H Armenian, MD, MPH13, June-Wha Rhee, MD14
AFFILIATIONS
1 City of Hope National Medical Center, Duarte, California, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 City of Hope National Medical Center, Duarte, California, United States
4 City of Hope National Medical Center, Duarte, California, United States
5 City of Hope National Medical Center, Duarte, California, United States
6 City of Hope National Medical Center, Duarte, California, United States
7 City of Hope National Medical Center, Duarte, California, United States
8 City of Hope National Medical Center, Duarte, California, United States
9 City of Hope National Medical Center, Duarte, California, United States
10 City of Hope National Medical Center, Duarte, California, United States
11 City of Hope National Medical Center, Duarte, California, United States
12 City of Hope National Medical Center, Duarte, California, United States
13 City of Hope National Medical Center, Duarte, California, United States
14 City of Hope National Medical Center, Duarte, California, United States
ABSTRACT
Background: Patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT) are at increased risk of cardiovascular disease and non-relapse mortality (NRM). Coronary artery calcium (CAC), a marker of subclinical coronary atherosclerosis, improves risk stratification beyond traditional cardiovascular risk factors and supports targeted initiation of guideline-recommended therapies, particularly statins. Patients with AML or MDS may be particularly vulnerable to the clinical consequences of pre-existing atherosclerosis because of the myeloid malignancy-associated inflammation and thrombosis, prior cytotoxic therapy or radiation, HCT-related endothelial injury, Graft-versus-host disease and subsequent cardiotoxic therapies further increase risk. CAC may also reflect cumulative vascular injury, biologic aging, and comorbidity burden relevant to NRM. However, its association with post-HCT outcomes in this population remains poorly understood. We evaluated the association between pre-HCT CAC severity and mortality, as well as statin use in patients with CAC.
Methods: This retrospective cohort study included consecutive patients with AML or MDS who underwent allogeneic HCT at City of Hope between 2017 and 2023 and had a non-gated chest computed tomography (CT) scan during the year preceding HCT. CAC was on these scans using an FDA-cleared artificial intelligence algorithm and categorized by Agatston (Ag) score as none (0), mild (1-99), moderate (100-299), or severe (300). Baseline characteristics, cardiovascular risk factors (hypertension, diabetes, and dyslipidemia), statin use at 1 year, and post-HCT outcomes, including cause of death, were abstracted from the medical record. Multivariable Cox regression estimated the association between CAC severity and 1-year all-cause mortality, reported as hazard ratios (HR) and 95% confidence intervals (CIs). Survival probabilities were estimated using the Kaplan-Meier method and compared with the log-rank test. NRM was evaluated using cumulative incidence and Fine-Gray regression, with relapse-related mortality treated as a competing event.
Results: A total of 747 patients were included (44% female; mean age at HCT, 59 years), of whom 66% had AML and 34% had MDS. CAC was present in 42% of patients before HCT; 21% had mild, 11% had moderate, and 10% had severe CAC. Overall 1-year survival was 85%. Patients with moderate or severe CAC had significantly lower 1-year survival than those with no or mild CAC (77% vs. 87%; p=0.002). After adjustment for demographics, disease, transplant, and cardiovascular risk factors, moderate-to-severe CAC (Ag score ≥100) remained independently associated with 1-year all-cause mortality (HR 1.56, 95% CI 1.02–2.39; reference: Ag score <100). Severe CAC (Ag score ≥300) was also associated with increased NRM at 1 year (HR 2.20, 95% CI 1.06-4.56; p=0.034) and 5 years (HR 2.05, 95% CI 1.05-3.97; p=0.034), although both estimates were attenuated after multivariable adjustment. Among the 253 patients with CAC who were alive 1 year after HCT, only 31% were receiving statin therapy at 1 year.
Conclusions: In patients with AML or MDS undergoing allogeneic HCT, CAC was present in more than 40%, and moderate-to-severe CAC was independently associated with early mortality. Severe CAC was also associated with higher NRM in unadjusted analyses. Low statin use highlights a potentially modifiable post-HCT cardiovascular prevention gap, warranting further study of statin therapy in this population. Opportunistic CAC assessment on routine pre-HCT CT scans could strengthen risk stratification and identify patients who warrant cardiovascular evaluation, risk-factor optimization, and closer post-HCT surveillance.
DISCLOSURES
Stephanie Wu, MD: No relevant conflicts of interest to declare.